Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055146 · ClinicalTrials.gov registry record · Phase 2
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study of Leukemia, Lymphocytic, Chronic, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 14
- Study locations
NCT00055146: Completed Phase 2 study of Leukemia, Lymphocytic, Chronic, sponsored by Eisai.
NCT00055146 is a Phase 2 study of Leukemia, Lymphocytic, Chronic that has completed, run by Eisai. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055146, a Phase 2 study of Leukemia, Lymphocytic, Chronic, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)
Conditions Studied
Interventions
- DRUG ONTAK
Study Locations (14)
California
- Pacific Coast Hematology/Oncology Medical Group, Inc. - Fountain Valley
- UCSD School of Medicine - La Jolla
Other
- Montecaseros - Mendoza
- Oncology Day Unit, Frankston Hospital - Frankston
São Paulo
- Hospital de Cancer de Barretos - Fundacao Pio XII - Barretos
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - São Paulo
Illinois
- Rush-Presbyterian St. Luke's Cancer Center - Chicago
New York
- Weill Medical College of Cornell University/New York Presbyterian Hospital - New York
Texas
- University of Texas, M.D. Anderson Cancer Center - Houston
Victoria
- Peter MacCallum Cancer Institute - East Melbourne
Goiás
- Hospital Araujo Jorge - Associacao de Combate ao Cancer em Goias - Goiânia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00055146 record still lists
NCT00055146 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Leukemia, Lymphocytic, Chronic appearing as the primary indexed condition, and to 1 intervention - of which ONTAK is the first listed.
NCT00055146 lists 14 locations in 11 states (California, Other, São Paulo).
Frequently Asked Questions
What is clinical trial NCT00055146 about?
NCT00055146 is a clinical study titled "Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)". The purpose of this study is to evaluate the safety and effectiveness of ONTAK in previously treated patients with chronic lymphocytic leukemia (CLL)
What is the current status of trial NCT00055146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2003-03. Estimated completion is 2006-05.
What conditions does trial NCT00055146 study?
This clinical trial studies the following conditions: Leukemia, Lymphocytic, Chronic.
What interventions are being tested in trial NCT00055146?
The interventions under investigation include: ONTAK (DRUG).
Who is sponsoring clinical trial NCT00055146?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055146 being conducted?
This trial has 14 study locations across California, Illinois, New York, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Lymphocytic, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00055146's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia